US2022143121A1PendingUtilityA1

Therapeutic treatment for the coronavirus disease covid-19

67
Assignee: MOLLICK PETER JOSEPHPriority: Apr 2, 2020Filed: Apr 1, 2021Published: May 12, 2022
Est. expiryApr 2, 2040(~13.7 yrs left)· nominal 20-yr term from priority
A61K 36/53A61P 31/12A61K 9/0095A61K 9/4833A61K 9/20A61P 31/14A61K 9/0053A23L 33/105
67
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A therapeutic treatment for the treatment of COVID-19 disease, the treatment to be initiated soon after and preferably within approximately twenty four hours after the patient develops the first signs of symptoms comprising but not limited to individually or in combination thereof fever, headache, sore joints, cough, fatigue, chills. The treatment consists of the oral administration of the herb thyme, also know as common thyme ( Thymus vulgaris ). The treatment is thought to inhibit the replication and activity of the virus allowing the patient to regain normal health and assist in developing immunity to the virus. The treatment is not known to completely eliminate the virus from the patient therefore resulting in the patient possibly developing the same or different symptoms of the disease a second, or more times requiring additional treatments of the disclosed thyme therapeutic treatment.

Claims

exact text as granted — not AI-modified
I claim: 
     
         1 . A composition for oral ingestion for use in the treatment of the disease Covid-19, the composition comprising
 one or more extracted components of the whole leaf of the herb thyme.   
     
     
         2 . The composition of  claim 1  in a ground state. 
     
     
         3 . The composition of  claim 2  combined with a liquid. 
     
     
         4 . The composition of  claim 3  wherein the liquid comprises water. 
     
     
         5 . The composition of  claim 2  combined with food. 
     
     
         6 . The composition of  claim 2  encapsulated or formed into a pill. 
     
     
         7 . The composition of  claim 1  for use in the prevention of the disease Covid-19. 
     
     
         8 . The composition of  claim 7  in a ground state. 
     
     
         9 . The composition of  claim 8  combined with a liquid. 
     
     
         10 . The composition of  claim 9  wherein the liquid comprises water. 
     
     
         11 . The composition of  claim 8  combined with food. 
     
     
         12 . The composition of  claim 8  encapsulated or formed into a pill. 
     
     
         13 . The substance thymol in a synthetic form for use in the treatment of the disease Covid-19. 
     
     
         14 . The substance thymol derived from the herb thyme, for use in the treatment of the disease Covid-19. 
     
     
         15 . The composition of  claim 1  comprising any one of individually the constituents or in combination thereof the constituents, the constituents being, thymol, camphor, borneol, carvacrol, terpinenes, pinenes, cymene, terpinenols, citral and cineoles, for use in the treatment or prevention of the disease Covid-19. 
     
     
         16 . A method for using the composition of  claim 1  for use in the treatment of the disease Covid-19 disease in a patient experiencing the beginning stages of the symptoms of the disease, the treatment beginning within approximately twenty-four hours after the onset of COVID-19 symptoms that may comprise of but are not limited to individually or limited to in combination thereof; fever, headache, sore joints, cough, fatigue, and chills, the method of use comprising the steps of:
 i) orally ingesting a first dose of the one or more extracted components of the whole leaf of the herb thyme. 
 ii) orally ingesting a second dose of the one or more extracted components of the whole leaf of the herb thyme within approximately six to eight hours after the first dose of the herb thyme, and 
 iii) orally ingesting a third dose of the one or more extracted components of the whole leaf of the herb thyme within approximately six to eight hours after the second dose of the herb thyme. 
 
     
     
         17 . The method of  claim 16  wherein the one or more extracted components of the whole leaf of the herb thyme is orally ingested with a liquid. 
     
     
         18 . The method of  claim 17  wherein the liquid comprises water. 
     
     
         19 . The method of  claim 16  wherein the one or more extracted components of the whole leaf of the herb thyme is orally ingested with food. 
     
     
         20 . (canceled)

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.